Emerald Advisers LLC Acquires 177,129 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Emerald Advisers LLC boosted its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 27.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 827,302 shares of the specialty pharmaceutical company's stock after purchasing an additional 177,129 shares during the quarter. Collegium Pharmaceutical makes up 1.2% of Emerald Advisers LLC's portfolio, making the stock its 23rd biggest position. Emerald Advisers LLC owned approximately 2.53% of Collegium Pharmaceutical worth $31,967,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. ProShare Advisors LLC raised its holdings in Collegium Pharmaceutical by 3.3% in the first quarter. ProShare Advisors LLC now owns 8,826 shares of the specialty pharmaceutical company's stock worth $343,000 after purchasing an additional 281 shares in the last quarter. Louisiana State Employees Retirement System raised its holdings in Collegium Pharmaceutical by 1.9% in the second quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company's stock worth $531,000 after purchasing an additional 300 shares in the last quarter. Texas Permanent School Fund Corp raised its holdings in Collegium Pharmaceutical by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 28,541 shares of the specialty pharmaceutical company's stock worth $1,108,000 after purchasing an additional 369 shares in the last quarter. SummerHaven Investment Management LLC raised its holdings in Collegium Pharmaceutical by 1.3% in the second quarter. SummerHaven Investment Management LLC now owns 34,773 shares of the specialty pharmaceutical company's stock worth $1,120,000 after purchasing an additional 452 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Collegium Pharmaceutical by 1.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 29,282 shares of the specialty pharmaceutical company's stock worth $1,137,000 after purchasing an additional 535 shares in the last quarter.

Collegium Pharmaceutical Stock Performance

Shares of Collegium Pharmaceutical stock traded down $0.68 during trading on Friday, hitting $33.46. 452,372 shares of the company's stock traded hands, compared to its average volume of 310,485. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.11 and a quick ratio of 1.04. Collegium Pharmaceutical, Inc. has a 1 year low of $21.40 and a 1 year high of $42.29. The stock has a market capitalization of $1.08 billion, a P/E ratio of 12.97 and a beta of 0.95. The business has a 50-day simple moving average of $37.51 and a 200-day simple moving average of $35.27.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The company had revenue of $145.28 million for the quarter, compared to analysts' expectations of $143.94 million. During the same period last year, the firm posted $1.13 earnings per share. Collegium Pharmaceutical's revenue was up 7.2% compared to the same quarter last year. As a group, analysts forecast that Collegium Pharmaceutical, Inc. will post 5.81 EPS for the current year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the firm's stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares of the company's stock, valued at approximately $1,970,741.92. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of the firm's stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the transaction, the executive vice president now directly owns 53,816 shares of the company's stock, valued at approximately $1,970,741.92. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm's stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the transaction, the executive vice president now directly owns 120,161 shares in the company, valued at $4,602,166.30. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 3.98% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on COLL shares. Needham & Company LLC reiterated a "hold" rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Piper Sandler reissued a "neutral" rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a research note on Friday, October 11th. StockNews.com cut Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, October 23rd. Truist Financial increased their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a "buy" rating in a research note on Friday, August 9th. Finally, HC Wainwright increased their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a "buy" rating in a research note on Thursday, September 5th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $42.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.